共 11 条
[4]
新型口服抗凝药物临床研究进展[J]. 高润霖. 中华医学杂志. 2013 (31)
[6]
Effect of hepatic impairment on the pharmacokinetics and pharmacodynamics of a single dose of rivaroxaban, an oral, direct F actor X a inhibitor[J] . Dagmar Kubitza,Angelika Roth,Michael Becka,Abir Alatrach,Atef Halabi,Holger Hinrichsen,Wolfgang Mueck. Br J Clin Pharmacol . 2013 (1)
[7]
Anticoagulant Therapy with the Oral Direct Factor Xa Inhibitors Rivaroxaban, Apixaban and Edoxaban and the Thrombin Inhibitor Dabigatran Etexilate in Patients with Hepatic Impairment[J] . Jochen Graff,Sebastian Harder. Clinical Pharmacokinetics . 2013 (4)
[8]
Monitoring plasma levels of factor Xa inhibitors: how, why and when?[J] . Samama,Amiral,Guinet,Flem,Seghatchian. Expert Review of Hematology . 2013 (2)
[9]
Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants ( Dabigatran , Rivaroxaban , Apixaban ) Versus Warfarin in Patients With Atrial Fibrillation[J] . Corey S. Miller,Sonia M. Grandi,Avi Shimony,Kristian B. Filion,Mark J. Eisenberg. The American Journal of Cardiology . 2012 (3)
[10]
Effects of renal impairment on the pharmacokinetics, pharmacodynamics and safety of rivaroxaban, an oral, direct Factor Xa inhibitor[J] . DagmarKubitza,MichaelBecka,WolfgangMueck,AtefHalabi,HaidarMaatouk,NorbertKlause,VolkmarLufft,Dominic D.Wand,ThomasPhilipp,HeikeBruck. British Journal of Clinical Pharmacology . 2010 (5)